HomeCompareXDNA vs EQR

XDNA vs EQR: Dividend Comparison 2026

XDNA yields 27.10% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 XDNA wins by $64.0K in total portfolio value
10 years
XDNA
XDNA
● Live price
27.10%
Share price
$7.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$111.8K
Annual income
$13,538.26
Full XDNA calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — XDNA vs EQR

📍 XDNA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodXDNAEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, XDNA + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
XDNA pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

XDNA
Annual income on $10K today (after 15% tax)
$2,303.52/yr
After 10yr DRIP, annual income (after tax)
$11,507.52/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, XDNA beats the other by $6,853.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of XDNA + EQR for your $10,000?

XDNA: 50%EQR: 50%
100% EQR50/50100% XDNA
Portfolio after 10yr
$79.8K
Annual income
$9,506.93/yr
Blended yield
11.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

XDNA
No analyst data
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

XDNA buys
0
EQR buys
0
No recent congressional trades found for XDNA or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricXDNAEQR
Forward yield27.10%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$111.8K$47.8K
Annual income after 10y$13,538.26$5,475.61
Total dividends collected$73.3K$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: XDNA vs EQR ($10,000, DRIP)

YearXDNA PortfolioXDNA Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$13,410$2,710.03$11,380$679.82+$2.0KXDNA
2$17,745$3,396.41$13,014$837.25+$4.7KXDNA
3$23,188$4,200.35$14,961$1,036.20+$8.2KXDNA
4$29,940$5,129.55$17,297$1,289.22+$12.6KXDNA
5$38,226$6,190.06$20,121$1,613.15+$18.1KXDNA
6$48,288$7,386.11$23,561$2,030.84+$24.7KXDNA
7$60,388$8,719.90$27,783$2,573.54+$32.6KXDNA
8$74,807$10,191.53$33,013$3,284.39+$41.8KXDNA
9$91,842$11,799.00$39,547$4,223.51+$52.3KXDNA
10$111,810$13,538.26$47,791$5,475.61+$64.0KXDNA

XDNA vs EQR: Complete Analysis 2026

XDNAStock

The adviser employs a “passive management” investment approach designed to track the total return performance of the index. The index is a rules-based index that consists of the stocks or corresponding depositary receipts of companies engaged in the creation, development, production, operation, provision, distribution, ownership, servicing, licensing, leasing or franchising of at least one of the DNA Modification Technology Business. The fund invests at least 80% of its net assets in DNA Modification Technology Companies. It is non-diversified.

Full XDNA Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this XDNA vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

XDNA vs SCHDXDNA vs JEPIXDNA vs OXDNA vs KOXDNA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.